Skip to main content

Clinical Trials Using Cemiplimab

Review the clinical trials studying cemiplimab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 62

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Status: Active
Location: 3 locations
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Status: Active
Location: 4 locations
Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients
Status: Active
Location: 3 locations
Immunotherapy with or without Chemotherapy for the Treatment of Metastatic or Unresectable Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Status: Active
Location: 2 locations
A Vaccine (VSV-IFNβ-NIS) in Combination with Cemiplimab and Ipilimumab for the Treatment of Recurrent Peripheral T-cell Lymphoma
Status: Active
Location: 2 locations
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Status: Active
Location: 4 locations
A Vaccine (VSV-hIFNβ-NIS) with or without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Status: Active
Location: 2 locations
A Microdevice for Candidate Drug Screening in Patients with Skin Squamous Cell Carcinoma
Status: Active
Location: 2 locations
Cemiplimab and Fianlimab before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer, N-PLANC Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Testing whether Cemiplimab (REGN2810) plus CDX-1140 Given Prior to Surgery are Better Than Cemiplimab (REGN2810) Alone in Patients with Stage III-IV Head and Neck Cancer
Status: Active
Location: JHU Sidney Kimmel Comprehensive Cancer Center LAO, Baltimore, Maryland
All-Trans Retinoic Acid and Cemiplimab for the Treatment of Patients with Metastatic or Locally Advanced, Unresectable Leiomyosarcoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Cetuximab and Cemiplimab before Surgery for the Treatment of Resectable Head and Neck Squamous Cell Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Ubamatamab Alone or in Combination with Cemiplimab for Patients with Locally Advanced or Metastatic Renal Medullary Carcinoma or Epithelioid Sarcoma that is MUC16-Expressing SMARCB1-Deficient
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cemiplimab and Cetuximab Prior to Salvage Surgery for Treatment of Recurrent Oral Cavity Squamous Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Biomarkers for Predicting Response to SAR444881 in Combination with Cemiplimab in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, or Ovarian Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immunotherapy in Combination with Radiation Therapy, with or without Platinum Doublet Chemotherapy, for the Treatment of Patients with Stage II or III Locally Advanced and Unresectable Non-Small Cell Lung Cancer, TRIPL Trial
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Cemiplimab with or without Fianlimab for the Treatment of Older Patients with Localized or Locally Advanced MSI-H Colorectal Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Cemiplimab and Transarterial Radioembolization with Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Chemotherapy and Cemiplimab with or without Alirocumab before Surgery for the Treatment of Lung Cancer in Patients with Stage IB-IIIA Non-small Cell Lung Cancer
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Cemiplimab with or without Chemotherapy followed by Biomarker Guided De-escalated Therapy for the Treatment of Patients with HPV-related Oropharyngeal Squamous Cell Cancer, MINIMA Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Dupilumab and Cemiplimab for the Treatment of Early-Stage, Resectable Non-small Cell Lung Cancer
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Adagrasib, Cetuximab, and Cemiplimab for the Treatment of Patients with Advanced or Metastatic Colorectal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas